Atea

May 10, 2022

•

Mar 31, 2022

Atea Q1 2022 Earnings Report

Atea Pharmaceuticals reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Key Takeaways

Atea Pharmaceuticals reported a net loss of $42.1 million for the first quarter of 2022, compared to a net income of $30.7 million for the same period in 2021. The company highlighted new bemnifosbuvir data showing clinical benefits in two placebo-controlled trials and the initiation of a Phase 2 global study and human challenge trial with AT-752 for dengue.

New clinical results from MORNINGSKY trial showed a 71% reduction in hospitalization in COVID-19 patients treated with bemnifosbuvir versus placebo.

Final analysis of Phase 2 hospitalized study in high-risk COVID-19 patients suggested potential clinical benefits with bemnifosbuvir versus placebo.

New in vitro results demonstrated bemnifosbuvir retains antiviral activity against all SARS-CoV-2 variants of concern, including Omicron (BA.1).

Atea initiated a Phase 2 global study and human challenge trial with AT-752 as a potential first-in-class antiviral treatment for dengue.